Renaissance Technologies LLC decreased its position in Intec Pharma Ltd (NASDAQ:NTEC) by 51.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,100 shares of the biotechnology company’s stock after selling 45,798 shares during the quarter. Renaissance Technologies LLC owned approximately 0.13% of Intec Pharma worth $244,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Intec Pharma by 2,096.1% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 658,835 shares of the biotechnology company’s stock valued at $3,722,000 after buying an additional 628,835 shares during the period. ARK Investment Management LLC purchased a new position in shares of Intec Pharma during the third quarter valued at about $609,000. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Intec Pharma by 13.0% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 589,996 shares of the biotechnology company’s stock valued at $3,333,000 after buying an additional 67,929 shares during the period. Finally, PNC Financial Services Group Inc. increased its position in shares of Intec Pharma by 50.0% during the third quarter. PNC Financial Services Group Inc. now owns 75,000 shares of the biotechnology company’s stock valued at $424,000 after buying an additional 25,000 shares during the period. Hedge funds and other institutional investors own 39.68% of the company’s stock.

NASDAQ:NTEC opened at $7.88 on Tuesday. Intec Pharma Ltd has a one year low of $3.55 and a one year high of $8.78. The stock has a market cap of $259.98 million, a P/E ratio of -4.78 and a beta of 0.39.

Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.03. On average, analysts expect that Intec Pharma Ltd will post -1.31 EPS for the current fiscal year.

Several brokerages recently issued reports on NTEC. Zacks Investment Research upgraded shares of Intec Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday. ValuEngine upgraded shares of Intec Pharma from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $11.96.

ILLEGAL ACTIVITY WARNING: “Renaissance Technologies LLC Has $244,000 Holdings in Intec Pharma Ltd (NTEC)” was first reported by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2019/02/12/renaissance-technologies-llc-has-244000-holdings-in-intec-pharma-ltd-ntec.html.

Intec Pharma Company Profile

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

See Also: Stock Symbol

Want to see what other hedge funds are holding NTEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intec Pharma Ltd (NASDAQ:NTEC).

Institutional Ownership by Quarter for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.